Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1225069-85-1

Post Buying Request

1225069-85-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1225069-85-1 Usage

Description

3-3-(Trifluoromethyl)benzoylaminobenzene-boronic acid pinacol ester is a boronic acid pinacol ester derivative that is commonly used in organic synthesis. It contains a trifluoromethyl group, which enhances the reactivity and selectivity of the compound in various reactions.

Uses

Used in Organic Synthesis:
3-3-(Trifluoromethyl)benzoylaminobenzene-boronic acid pinacol ester is used as a reagent for the Suzuki-Miyaura cross-coupling reaction, a widely used method for carbon-carbon bond formation. Its trifluoromethyl group improves the reactivity and selectivity of the compound in these types of reactions.
Used in Pharmaceutical Synthesis:
3-3-(Trifluoromethyl)benzoylaminobenzene-boronic acid pinacol ester is used as a building block in the synthesis of pharmaceuticals. Its unique structure and reactivity make it an important component in the development of new drugs.
Used in Agrochemical Synthesis:
3-3-(Trifluoromethyl)benzoylaminobenzene-boronic acid pinacol ester is also used as a building block in the synthesis of agrochemicals. Its properties contribute to the development of effective and selective pesticides and other agricultural chemicals.

Check Digit Verification of cas no

The CAS Registry Mumber 1225069-85-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,5,0,6 and 9 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1225069-85:
(9*1)+(8*2)+(7*2)+(6*5)+(5*0)+(4*6)+(3*9)+(2*8)+(1*5)=141
141 % 10 = 1
So 1225069-85-1 is a valid CAS Registry Number.

1225069-85-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H32372)  3-[3-(Trifluoromethyl)benzoylamino]benzene boronic acid pinacol ester, 95%   

  • 1225069-85-1

  • 500mg

  • 6831.0CNY

  • Detail

1225069-85-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(trifluoromethyl)benzamide

1.2 Other means of identification

Product number -
Other names N-[3-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(trifluoromethyl)benzamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1225069-85-1 SDS

1225069-85-1Downstream Products

1225069-85-1Relevant articles and documents

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma

Wang, Qi,Dai, Yang,Ji, Yinchun,Shi, Huanyu,Guo, Zuhao,Chen, Danqi,Chen, Yuelei,Peng, Xia,Gao, Yinglei,Wang, Xin,Chen, Lin,Jiang, Yuchen,Geng, Meiyu,Shen, Jingkang,Ai, Jing,Xiong, Bing

, p. 671 - 689 (2019/01/04)

Although lung adenocarcinoma patients have benefited from the development of targeted therapy, patients with lung squamous cell carcinoma (SqCC) have no effective treatment due to the complexity and heterogeneity of the disease. Therefore, basing on the genetic analysis of mutations in lung squamous cell carcinoma to design multi-target inhibitors represents a potential strategy for the medical treatment. In this study, through screening an in-house focused library, we identified an interesting indazole scaffold. And following with binding analysis, we elaborated the structure-activity relationship of this hit compound by optimizing four parts guided by the DDR2 enzymatic assay, which resulted in a potent lead compound 10a. We conducted further optimization of dual enzymatic inhibitions towards FGFR1 and DDR2, two important kinases in lung squamous cell carcinoma. Finally, from the cellular antiproliferative activity tests and in vivo pharmacokinetic test, 3-substituted indazole derivative 11k was found to be a promising candidate and subjected to in vivo pharmacology study with the mouse xenograft models, demonstrating profound anti-tumor efficacy. Additional in vitro druglike assessment reinforced that compound 11k could be valuable for SqCC drug development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1225069-85-1